Reports of “Ozempic parties” followed, and, as the drug’s popularity surged, supply became a drag in various countries.

The use of semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1 RA), is not associated with an increased risk for ...

Semaglutide remains on the agency’s drug shortage list, but all FDA-approved forms of the drug are no longer labeled ...

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar ...

Semaglutide, the active ingredient in Ozempic, has shown promising results in weight loss and blood sugar management. But did ...

A new study published in the New England Journal of Medicine showed that once-weekly injectable semaglutide led to ...

Results were announced from a phase 3 clinical trial evaluating subcutaneous semaglutide in overweight patients with cardiovascular disease.

The ‘Ozempic drug,’ semaglutide, has been found to reduce moderately severe pain caused by knee osteoarthritis and improve ...

Drugmaker Lupin aims to be part of the first wave of generic drugmakers to make GLP-1 receptor agonists products, used to ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

The FDA, however, warns that reports in a database aren’t yet verified and don’t mean the drugs have actually caused the harms reported.

The most popular GLP-1 agonist is semaglutide, known by the brand names Wegovy and Ozempic, andhere have been 23 suspected UK ...